CAMPBELL BROTHERS LIMITED

ACN 009 657 489

PROSPECTUS

for an underwritten renounceable 1 for 5 rights issue

UNDERWRITER

ABN AMRO MORGANS CORPORATE LIMITED

This prospectus is signed for the purposes of section 351 of the Corporations Act.

Greg F Kilmister
Managing Director
22/11/05

This prospectus contains important information for you as a shareholder and requires your immediate attention. If you are in any doubt about its contents or the course of action you should take, consult your broker or other professional advisor as soon as possible.

LETTER FROM THE CHAIRMAN

CAMPBELL BROTHERS
LIMITED

22 November 2005

Dear Shareholder

I am pleased to introduce to you our 2005 rights issue prospectus.

The Company is offering to shareholders one fully paid ordinary share for every five shares already held. The issue price is $9.00 per share, which represents a discount of approximately 12.6% to the closing market price of shares on ASX of $10.30 on 21 November 2005, the last day the shares traded before the date of this prospectus. The offer is renounceable, which means that rights may be traded on the Australian Stock Exchange or otherwise transferred if you do not wish to take up some or all of the new shares to which you are entitled. Shareholders who take up their full entitlement will be able to apply for additional shares at the same issue price, being $9.00 per share.

The rights issue is underwritten by ABN AMRO Morgans Corporate Limited and will raise approximately $75 million.

Net Profit after tax before unusual items for the September 2005 half year was $17.4 million, an increase of 27.6% on the $13.6 million for the corresponding period last year, on a like for like basis following restatement for the effect of International Financial Reporting Standards (IFRS). Our expectations are that the full year result before unusual items will show a substantial increase on the record result achieved last year.

The profit for the September half year was generated from revenue of $250.7 million, up 15 per cent on the $218.0 million recorded for the corresponding period last year.

This strong performance improvement is a result of the Company's growth and diversification strategy implemented over recent years. That strategy involves a balanced mix of organic growth and targeted acquisitions, particularly in the group's highly successful laboratory services business.

The Company will pay shareholders an interim fully franked dividend of 21 cents, a 3 cent increase over the interim dividend paid last year. The dividend will be paid on 20 December 2005 based on shares held at 2 December 2005. The rights issue shares are not eligible for the interim dividend. The shares issued under this rights issue will rank equally with all other ordinary shares and, in particular, will be eligible to receive in full any final dividend to be paid in July 2006 in respect of the year ending 31 March 2006.

Further growth and, importantly, diversification in the laboratory services business is likely to include already identified potential acquisitions in Europe, North America, Australia and Asia. A number of these acquisitions are quite substantial and will require additional funding. Company executives are working on these acquisitions at the moment and further details are likely to be released over coming months.

The acquisitions will be funded from the proceeds of the equity raising and existing debt facilities. The Board believes the equity raising will enhance the Company's financial base to take advantage of future strategic opportunities in core business areas as they occur.

As a shareholder you may accept all or part of your rights to participate in this issue of shares. Shareholders who take up their full entitlement will be able to apply for additional shares at the same price, being $9.00 per share. Details of the issue and how to participate in the issue can be found in the prospectus. Shareholders who are in any doubt as to how they should respond to this offer should consult their broker or other professional adviser.

This Company has enjoyed very strong shareholder support over many years. We look forward to your participation in the rights issue and your continued support.

Yours sincerely

Geoff McGrath
Chairman

THE ISSUE

Campbell Brothers Limited (**'Company'**) offers to each of its shareholders 1 fully paid ordinary share for every 5 shares already held by the shareholder at the record date.

The issue price is $9.00 per share and the issue will raise approximately $75 million (before costs of the issue).

The issue is a renounceable rights issue. Rights may be traded on Australian Stock Exchange Limited (ASX) or otherwise transferred if you do not wish to take up some or all of the new shares to which you are entitled.

Instructions on the actions you can take to accept all or part of your rights, apply for additional shares or to sell all or part of your rights are on the rights entitlement and acceptance form accompanying this prospectus.

Fractional entitlements will be rounded up. Your entitlement is shown in the personalised rights entitlement and acceptance form accompanying this prospectus.

If a rights entitlement and acceptance form does not accompany this prospectus, please contact the Company's share registry at the address set out below or on telephone number +61 3 9415 4000 or 1300 552 270 (within Australia).

KEY DATES

Announcement of rights issue and lodgement of prospectus	22 November 2005
Notice sent to shareholders	24 November 2005
Shares quoted ex rights and rights trading commences	25 November 2005
Record date	1 December 2005
Prospectus despatched to shareholders	6 December 2005
Last day for rights trading on ASX	13 December 2005
Closing date for acceptances (5.00 pm, Brisbane time)	**20 December 2005**
Despatch of holding statements	3 January 2006
New shares expected to commence trading on ASX on a normal settlement basis	4 January 2006

The directors may, with the consent of the underwriter, extend the closing date for acceptances or vary the issue and despatch date. In the case of an extension, the key dates after the closing date will be affected.

The Company reserves the right to close the issue at any time and refund application money without interest.

ASX QUOTATION

The Company has applied for quotation on ASX of the shares offered under this prospectus.

If official quotation of those shares is not granted by ASX before the expiration of three months after the date of this prospectus (or such longer period as may be allowed by the Australian Securities and Investments Commission ('ASIC')), the Company will not allot or issue any shares and will repay all application money within the time prescribed under the Corporations Act, without interest.

TERMS OF THE ISSUE

Accepting your share entitlement

The issue price is $9.00 per share. You may accept all or part of your rights.

To accept the shares offered to you in this rights issue you should -

- complete the rights entitlement and acceptance form accompanying this prospectus
- draw a cheque in Australian currency for the application money payable to '**Campbell Brothers Limited - Application Account**'
- return the form and cheque to the Company's share registry -

Computershare Investor Services Pty Limited
Level 19
307 Queen Street
Brisbane, QLD 4001

Postal address:

Reply Paid
GPO Box 523
Brisbane, QLD 4001
(a reply paid envelope is provided)

Alternatively you can pay the application money using Bpay in accordance with the instructions on the rights entitlement and acceptance form accompanying this prospectus. If you do so, you do not need to complete and return the form.

The deadline for acceptances is 5.00 pm, Brisbane time, on Tuesday **20 DECEMBER 2005**.

By forwarding payment for more shares than your entitlement or more shares than you specify in your entitlement and acceptance form, you will have applied for the maximum number of shares represented by the payment you have made.

Application monies will be held on trust for applicants until the issue of the new shares. Interest earned on application monies will be, and will remain, the property of the Company, whether or not the shares are issued.

If you wish to take up all of your entitlement and apply for Additional Shares

Shareholders may, in addition to taking up all of their entitlement, apply for additional shares. Additional shares will only be available where there is a shortfall between applications received or taken to have been received from shareholders (or persons to whom rights have been transferred or sold) for their entitlement and the number of new shares proposed to be issued under the rights issue.

If you are applying for additional shares, you only need to submit one completed entitlement and acceptance form to the Company's share registry at the address above or make one Bpay payment. By applying for more shares than your entitlement without identifying that you are applying for additional shares, you will be making an application for the excess shares as additional shares. Your cheque, bank draft or Bpay payment should be for the full amount of your application being:

- the amount payable in relation to your entitlement; and
- the amount payable in relation to any additional shares for which you have applied.

The completed entitlement and acceptance form, together with your bank cheque or bank draft for the application monies (made payable to **'Campbell Brothers Limited – Application Account'**) or your Bpay payment, must be received by no later than 5.00 pm, Brisbane time, on Tuesday **20 DECEMBER 2005.**

Shareholders are assured of receiving their entitlement in full. If the number of additional shares applied for is less than that available from the shortfall, all shareholders will be allocated the number of additional shares applied for in full. If more additional shares are applied for than are available from the shortfall under the rights issue, the underwriter, in consultation with the Company, will scale back those applications in their absolute discretion and excess application monies will be refunded without interest. No additional shares will be issued which will result in a shareholder increasing its voting power above 20%.

There is no assurance that shareholders will be allocated any additional shares and by applying for additional shares, you are bound to accept a lesser number of shares as determined by the underwriter, in consultation with the Company.

If there remains a shortfall after the allocation of additional shares, the underwriter will take up the shortfall in accordance with the underwriting agreement.

Rights trading

The issue is a renounceable rights issue. Trading in the rights will commence on ASX on 25 November 2005 and finish on 13 December 2005. If you wish to sell your rights, we suggest you consult your broker or other professional adviser.

Shares

The shares issued under this prospectus are ordinary shares in the Company. The shares will not be entitled to the interim dividend declared for the Company's half year ended on 30 September 2005. Once issued, they will rank equally with the shares currently on issue and, in particular, will be fully entitled to any final dividend declared for the financial year ending 31 March 2006.

Underwriting

The issue is underwritten by ABN AMRO Morgans Corporate Limited (the underwriter) subject to the underwriting agreement (see the Additional Information section of this prospectus).

Overseas Shareholders

The offer of shares in this prospectus will only be made to shareholders with registered addresses in Australia and New Zealand. The offer of shares in this prospectus does not constitute an offer in any place where it would be unlawful for such an offer to be made.

In making the offer of shares to shareholders in New Zealand, the company is relying on the Securities Act (Overseas Companies) Exemptions Notice 2002 (NZ) by virtue of which this Prospectus is not required to be registered in New Zealand.

The offer of shares in this prospectus will not be made to shareholders with registered addresses in countries other than Australia and New Zealand, given the small number of shareholders in each place and the cost of complying with local regulations in those countries. In accordance with ASX Listing Rules, rights equivalent to those shareholders' rights will be offered to the underwriter who will endeavour to arrange for the sale of the rights and for the proceeds (less expenses of sale) to be distributed to those shareholders.

Neither the Company nor the underwriter is responsible for selling the rights at any particular time, at any particular price or in a particular manner. Neither the Company nor the underwriter is responsible for the number of rights sold or the price achieved on the sale of the rights for overseas shareholders.

Shareholders holding shares on behalf of persons who are resident overseas are responsible for ensuring that taking up their entitlement does not breach regulations in the relevant overseas jurisdiction. Return of a duly completed entitlement and acceptance form or your payment will be a representation that there has been no breach of such regulations. Shareholders who are nominees are therefore advised to seek independent advice as to how they should proceed.

EFFECT OF THE ISSUE

Proceeds

The Company will use the proceeds of the issue as follows:

	$'000
• Acquisition Funding	$73,800
• Costs of the issue (including underwriter's fees)	$1,200
Total funds raised (approximate)	$75,000

Further growth and importantly, diversification in the laboratory services business will likely include already identified potential acquisitions in Europe, North America, Australia and Asia. A number of these acquisitions are quite substantial and will require additional funding. Company executives are working on these acquisitions at the moment and further details are likely to be released over coming months.

Effect of Share Issue

The issue is a pro rata issue to shareholders. Shareholders who take up their full rights entitlement will not have their percentage shareholdings in the Company diluted. Shares which are not taken up will be available to other shareholders who apply for additional shares under this rights issue and any remaining shares will then be available to the underwriter who may offer those shares to investors other than existing shareholders.

The percentage shareholdings of shareholders who sell any of their rights or who do not exercise all or part of their rights, will be diluted.

Effect on Issued Capital and Balance Sheet

	Numbers of shares
Issued capital before the rights issue - fully paid ordinary shares	41,637,292
Fully paid ordinary shares to be issued under this rights issue*	8,327,458
Issued capital after the rights issue*	49,964,750

*These figures are estimates. The exact figures cannot be calculated until after entitlements are determined following the record date.

The pro forma condensed consolidated balance sheet of Campbell Brothers Limited and its Controlled Entities below is extracted from its reviewed condensed consolidated financial report for the 6 month period ended 30 September 2005. It is adjusted to show the receipt of the issue proceeds and payment of issue costs as if they had occurred on 30 September 2005.

The issue costs will be deducted from the issued capital account. This is reflected in the pro forma balance sheet below.

Campbell Brothers Limited and its Controlled Entities Condensed Consolidated Balance Sheet as at 30 September 2005

	Consolidated Actual $000	Adj	Consolidated Pro-forma $000
CURRENT ASSETS			
Cash and cash equivalents	15,627	73,800	89,427
Trade and other receivables	87,879		87,879
Inventories	44,482		44,482
Other	5,844		5,844
TOTAL CURRENT ASSETS	153,832	73,800	227,632
NON-CURRENT ASSETS			
Investments accounted for using equity method	2,207		2,207
Property, plant & equipment	93,067		93,067
Intangible assets	71,337		71,337
Deferred tax assets	7,968		7,968
Other	462		462
TOTAL NON-CURRENT ASSETS	175,041		175,041
TOTAL ASSETS	328,873	73,800	402,673
CURRENT LIABILITIES			
Trade and other payables	45,582		45,582
Interest bearing liabilities	4,410		4,410

Current tax liabilities	3,733		3,733
Provisions	9,087		9,087
TOTAL CURRENT LIABILITIES	62,812		62,812
NON-CURRENT LIABILITIES			
Borrowings	97,086		97,086
Deferred tax liabilities	3,181		3,181
Provisions	2,245		2,245
Other	199		199
TOTAL NON-CURRENT LIABILITIES	102,711		102,711
TOTAL LIABILITIES	165,523		165,523
NET ASSETS	163,350	73,800	237,150
EQUITY			
Issued capital	115,039	73,800	188,839
Reserves	1,309		1,309
Retained earnings	45,314		45,314
Total parent entity interest	161,662	73,800	235,462
Minority interests	1,688		1,688
TOTAL EQUITY	163,350	73,800	237,150

ADDITIONAL INFORMATION

Statutory Information

This prospectus is dated 22 November 2005. A copy of this prospectus was lodged with the ASIC on 22 November 2005. The ASIC takes no responsibility for the contents of this prospectus. No shares will be allotted on the basis of this prospectus later than 22 December 2006.

The Company is a disclosing entity and therefore subject to regular reporting and disclosure obligations under the Corporations Act. Under those obligations, the Company is obliged to comply with all applicable continuous disclosure and reporting requirements in the ASX Listing Rules.

Copies of documents lodged by the Company under these obligations may be obtained from, or inspected at, an office of the ASIC or the ASX website (www.asx.com.au).

While acceptances remain open, the Company will provide, free of charge, to any person who asks for it, a copy of all or any of the following documents -

- the annual financial report for the Company for the year ended 31 March 2005
- the half-year financial report for the Company for the half year dated 30 September 2005
- any other continuous disclosure notices lodged by the Company since lodgement of the annual financial report and before lodgement of this prospectus.

All requests for copies of the above documents should be addressed to the Company Secretary, PO Box 2191, Milton BC, Qld, 4064, Australia (telephone (07) 3367 7900; facsimile (07) 3367 8156) or to investor@campbell.com.au.

Terms of Ordinary Shares

The following is a summary (though not an exhaustive or definitive statement) of the rights, privileges and restrictions which currently attach to ordinary shares and which will attach to the shares being issued under this prospectus. Full details of the rights attaching to shares are set out in the Company's constitution, a copy of which is available for inspection at the Company's office at Level 2, 299 Coronation Drive, Milton during normal office hours:

- Each shareholder is entitled to receive notice of and attend personally, by proxy, attorney or representative, any general meeting of the Company.
- Each shareholder has one vote on a show of hands and one vote per share on a poll for each fully paid share held.
- Holders of ordinary shares are entitled to receive dividends, if declared. The directors may declare final and interim dividends and fix the time and method of payment.
- Subject to the rights of persons (if any) entitled to shares with special rights in a winding up and to the provisions of the Corporations Act, all monies and property that are to be distributed among members on a winding up will be distributed in proportion to the amounts paid up on the shares held by them.
- Subject to the constitution, the Corporations Act and the ASX Listing Rules, ordinary shares are transferable.
- The directors may, subject to the provisions of the constitution, the Corporations Act and the ASX Listing Rules, allot, grant options over, or otherwise deal with or

dispose of, shares in the Company as the directors think fit.

- Shareholders may from time to time, by special resolution, vary the rights conferred on holders of any of the issued shares or vary the provisions of the constitution.

Underwriting Agreement

The Company has entered into an underwriting agreement with ABN AMRO Morgans Corporate Limited, the underwriter. Under the terms of the underwriting agreement, the underwriter is entitled to a total underwriting fee of 1.5% of the amount raised (approximately $1,125,000).

If there is a shortfall in acceptances, the underwriter must, subject to the underwriting agreement, deliver to the Company within 6 business days of the closing date for acceptances, applications for shares not taken up by holders of the rights or issued to shareholders who apply for additional shares under this prospectus. The underwriter may appoint sub-underwriters to sub-underwrite the issue.

The underwriter is responsible for paying all issue management charges, sub-underwriting fees, handling fees, brokerage, stamping and other charges incurred by the underwriter.

The Company has made a number of representations and warranties to the underwriter including that this prospectus complies with the requirements of the Corporations Act and that the Company has complied with its continuous disclosure requirements. The Company has indemnified the underwriter and its directors, officers, employees and advisors against losses caused to the underwriter if these representations and warranties are wrong and claims in relation to the issue or this prospectus.

The underwriter may terminate the agreement and be released from its obligations on the happening of any of the events listed below. In relation to events numbered 5 - 17, the underwriter must first determine reasonably and in good faith that the event has had a material adverse effect on the issue or could create a potential liability for the underwriter under the Corporations Act.

1. **(ASX Indices fall)** The All Ordinaries Index is, for three consecutive business days, at a level which is 90% or less than the level at the close of trading on the date of the underwriting agreement.

2. **(Change in law)** Any of the following occurs which does or is likely to prohibit, restrict or regulate the issue or materially reduces the level or likely level of acceptances:

   (a) the introduction by the relevant government of legislation into the parliament of the Commonwealth of Australia or of any State or Territory of Australia;

   (b) the public announcement of prospective legislation or policy by the Federal Government or the Government of any State or Territory; or

   (c) the adoption by ASIC or its delegates of any regulations or policy.

3. **(Listing)**

   (a) ASX makes any official statement to any person, or indicates to the Company or the underwriter that ASX approval of quotation of the shares will not be given; or

   (b) ASX approval has not been given before the closing date for acceptances.

4. **(Insolvency event)** An insolvency event occurs with respect to the Company or a related body corporate.

5. **(Default)** The Company is in material default of any of the terms and conditions of the underwriting agreement or breaches any warranty or covenant given or made by it under that agreement and that default or breach is either incapable of remedy or is not remedied within 5 business days after it occurs.

6. **(Failure to comply)** The Company or any related body corporate fails to comply with any of the following:

   (a) a clause of its constitution;

   (b) a statute;

   (c) any policy or guideline of ASIC or any other requirement, order or request made by or on behalf of ASIC or any governmental agency; or

   (d) any material agreement entered into by it.

7. **(Capital structure)** The Company or a related body corporate alters its capital structure without the prior written consent of the underwriter.

8. **(Constitution altered)** The constitution or any other constituent document of the Company or a related body corporate is amended without the prior written consent of the underwriter, which consent must not be unreasonably withheld.

9. **(Financial assistance)** The Company or a related body corporate seeks the approval of shareholders under section 260B of the Corporations Act, without the prior written consent of the underwriter.

10. **(Business)** The Company or a related body corporate:

    (a) disposes, or agrees to dispose, of the whole, or a substantial part, of its business or property; or

    (b) ceases or threatens to cease to carry on business,

    in either case without the prior written consent of the underwriter.

11. **(Hostilities)** There is an outbreak of hostilities (whether or not war has been declared) not presently existing, or a major escalation in existing hostilities occurs, involving any one or more of the following:

    (a) Australia;

    (b) the United Kingdom;

    (c) the United States of America;

    (d) the Peoples Republic of China; or

    (e) any member country of the Organisation of Petrol Exporting Countries.

12. **(Financial position)** A materially adverse change, or development involving a prospective materially adverse change, occurs in the financial or trading position of the Company or a related body corporate.

13. **(Prospectus)** Without limiting any other paragraph:

(a) there is a material omission from the prospectus;

(b) the prospectus contains a misleading or deceptive statement;

(c) a statement in the prospectus becomes misleading or deceptive;

(d) the prospectus does not comply with section 713 of the Corporations Act; or

(e) a matter referred to in section 719 of the Corporations Act occurs in respect of the prospectus.

14. (**Corporations Act**) Without limiting any other paragraph:

(a) ASIC applies for an order under section 1324B of the Corporations Act in relation to the prospectus and the application is not dismissed or withdrawn before the closing date for acceptances;

(b) a person gives a notice under section 730 of the Corporations Act in relation to the prospectus;

(c) ASIC gives notice of intention to hold a hearing in relation to the prospectus under section 739(2) of the Corporations Act or makes an interim order under section 739(3) of the Corporations Act; or

(d) any person (other than the underwriter) who consented to being named in the prospectus withdraws that consent.

15. (**Supplementary prospectus**) The underwriter reasonably forms the view that a supplementary or a replacement document must be lodged with ASIC under section 719 of the Corporations Act and the Company does not lodge a supplementary or a replacement document in the form, with the content and within the time reasonably required by the underwriter.

16. (**Indictable offence**) A director of the Company or a related body corporate is charged with an indictable offence relating to a financial or corporate matter.

17. (**Listing Rules**) The Company commits a material breach of the ASX Listing Rules.

18. (**Withdrawal of applications**) Any circumstance arises after lodgement of the prospectus that results in the Company being required to offer the applicants an opportunity to withdraw their applications for shares and be repaid their application money.

19. (**Repayment**) Any circumstance arises after lodgement of the prospectus that results in the Company being required to repay the application money received from applicants.

A copy of the underwriting agreement may be inspected at the Company's office at Level 2, 299 Coronation Drive, Milton, Queensland.

Directors' Interests

The nature and extent of the interest (if any) that any of the directors holds, or held at any time during the last 2 years in:

(a) the formation or promotion of the Company;

(b) property acquired or to be acquired by the Company in connection with:
   (i) its formation or promotion; or
   (ii) the rights issue; or

(c) the rights issue,

is set out below.

The amount that anyone has paid or agreed to pay, or the nature and value of any benefit anyone has given or agreed to give:

(a) to a director to induce them to become, or to qualify as, a director of the Company; and

(b) for services provided by a director in connection with:
   (i) the formation or promotion of the Company; or
   (ii) the rights issue,

is set out below.

The directors have interests in Campbell Brothers Limited shares (including interests of less than 100%) as follows –

Name	**Number of Securities**
Geoffrey J McGrath	151,448 shares
Greg F Kilmister	72,000 shares
Bruce R Brown	102,272 shares
Raymond G Hill	10,000 shares
Martin D Kriewaldt	41,906 shares
Antony J Love	39,166 shares
Nerolie Withnall	1,482 shares

In addition to his shares, Mr Kilmister holds 30,000 options to subscribe for shares issued under the Company's Executive Option and Employee Share Plan.

For the current financial year ending 31 March 2006, the non-executive directors are expected to receive directors' fees and superannuation contributions of up to $411,802 in total.

A director may be paid fees or other amounts as the directors determine where a director performs special duties or otherwise performs services outside the scope of the ordinary duties of a director. A director may also be reimbursed for out of pocket expenses incurred as a result of their directorship or any special duties.

Mrs Withnall was within the last two years a consultant to the legal firm, Minter Ellison, which will receive from the Company professional fees of approximately $60,000 (exclusive of GST) for legal services provided in relation to this prospectus.

Consents and Responsibility Statements

The following parties have consented to be named in this prospectus in the capacities described:

Name	**Capacity**
ABN AMRO Morgans Corporate Limited	Underwriter
Computershare Investor Services Pty Limited	Share Registry
KPMG	Auditors
Minter Ellison	Solicitors

Except as set out below, each of ABN AMRO Morgans Corporate Limited, Computershare Investor Services Pty Limited, KPMG and Minter Ellison to the maximum extent permitted by law, expressly disclaims and takes no responsibility for, any part of the Prospectus, other than the reference to its name and has not caused or authorised the issue of any part of this prospectus.

Minter Ellison has provided legal advice to the Company in relation to the issue and has been responsible for preparing the summary of the underwriting agreement contained in this prospectus and consents to its inclusion.

KPMG has consented to the inclusion in this prospectus of references to its review of the Company's condensed consolidated financial report for the half year ended 30 September 2005.

Computershare Investor Services has had no involvement in the preparation of any part of this prospectus other than the recording of its name as share registry for the Company. Computershare Investor Services has not caused or authorised the issue of this prospectus.

Interests of Named Advisers

The nature and extent of the interest (if any) that any of the advisers listed below holds, or held at any time during the last two years in:

(a) the formation or promotion of the Company; or

(b) property acquired or to be acquired by the Company in connection with:
    (i) its formation or promotion; or
    (ii) the rights issue,

is set out below.

The amount that anyone has paid or agreed to pay, or the nature and value of any benefit anyone has given or agreed to give for services provided by an adviser listed below in connection with:

(a) the formation or promotion of the Company; or

(b) the rights issue,

is set out below.

Name	**Interest**
ABN AMRO Morgans Corporate Limited	Underwriting fees - $1,125,000 (GST exclusive)
Minter Ellison	Legal fees - $60,000 (GST exclusive)
KPMG	Accounting fees - $10,000 (GST exclusive)

Each of the directors has consented to the lodgement of this prospectus under section 720 of the Corporations Act.

CORPORATE DIRECTORY

Chairman

Geoffrey J McGrath

Managing Director

Greg F Kilmister

Directors

Bruce R Brown
Raymond G Hill
Martin D Kriewaldt
Antony J Love
Nerolie Withnall

Company Secretary

Andrew Austin

Registered Office

Level 2, 299 Coronation Drive
Milton, Qld 4064
Telephone: (07) 3367 7900
Facsimile: (07) 3367 8156
Website: www.campbell.com.au

Share Registry

Computershare Investor Services Pty Limited
Level 19
307 Queen Street
Brisbane Qld 4000

Underwriter

ABN AMRO Morgans Corporate Limited
Level 29, Riverside Centre
123 Eagle Street
Brisbane Qld 4000

Solicitors

Minter Ellison
Level 22, Waterfront Place
1 Eagle Street
Brisbane, Qld 4000

Auditor

KPMG
Level 30, Central Plaza One
345 Queen Street
Brisbane Qld 4000

CAMPBELL BROTHERS
LIMITED